Payment overview · 2025
General Payments
$2,241.26
105 reported records · 19 companies
Healthcare provider profile · identity verified
Amy Jo Cleemput, CNS
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LIMA, OH · NPI 1568702678
Verified facts
What the public records show
CMS Open Payments records show Amy Jo Cleemput, CNS received $2,241.26 in general payments during 2025 across 105 reported records.
Janssen Biotech, Inc. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $409.30 | 18.3% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $298.30 | 13.3% | 26 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $270.34 | 12.1% | 14 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $260.95 | 11.6% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $147.24 | 6.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.25 | 6.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $130.87 | 5.8% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $120.58 | 5.4% | 5 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $104.16 | 4.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $94.24 | 4.2% | 5 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $61.78 | 2.8% | 2 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $40.62 | 1.8% | 2 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $35.09 | 1.6% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $25.26 | 1.1% | 1 | 2025 |
| Verrica Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.03 | 0.9% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $20.88 | 0.9% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $20.72 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.02 | 0.8% | 1 | 2025 |
| Arcutis Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $18.63 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,963.04 | 101 |
| Education | $278.22 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $409.30 | 13 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $342.96 | 12 | 2025 |
Source payment records
|
|||||
| Sotyktu Normalized: sotyktu |
Drug | E.R. Squibb & Sons, L.L.C. | $270.34 | 14 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $178.11 | 19 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $142.25 | 3 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $126.25 | 6 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $126.25 | 6 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $126.25 | 6 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $120.58 | 5 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $120.19 | 7 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $104.16 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $94.24 | 5 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $78.62 | 5 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $65.23 | 2 | 2025 |
Source payment records
|
|||||
| ADBRY Normalized: adbry |
Biological | LEO Pharma Inc. | $61.78 | 2 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| YCANTH Normalized: ycanth |
Drug | Verrica Pharmaceuticals Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| Winlevi Normalized: winlevi |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Zoryve Normalized: zoryve |
Drug | Arcutis Biotherapeutics, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| Leqselvi Normalized: leqselvi |
Biological | SUN PHARMACEUTICAL INDUSTRIES INC. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 161 |
| Omeprazole | Omeprazole | 264 | 69 |
| Lisinopril | Lisinopril | 214 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 56 |
| Gabapentin | Gabapentin | 164 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 52 |
| Losartan Potassium | Losartan Potassium | 150 | 44 |
| Metformin Hcl | Metformin Hcl | 129 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 124 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 38 |
| Sertraline Hcl | Sertraline Hcl | 91 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 14 |
| Jardiance | Empagliflozin | 67 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 50 |
| Furosemide | Furosemide | 65 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 19 |
| Januvia | Sitagliptin Phosphate | 65 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 23 |
| Trazodone Hcl | Trazodone Hcl | 64 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 26 |
| Glimepiride | Glimepiride | 59 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 16 |
| Potassium Chloride | Potassium Chloride | 58 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 50 | 22 |
| Ezetimibe | Ezetimibe | 49 | 21 |
| Famotidine | Famotidine | 48 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 14 |
| Alendronate Sodium | Alendronate Sodium | 39 | 14 |
| Eliquis | Apixaban | 39 | 12 |
| Azithromycin | Azithromycin | 38 | 37 |
| Simvastatin | Simvastatin | 37 | 12 |
| Alprazolam | Alprazolam | 36 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 13 |
| Ozempic | Semaglutide | 31 | suppressed |
| Mupirocin | Mupirocin | 30 | 27 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | 11 |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,241.26 · 105 records | Janssen Biotech, Inc. | ADBRY, AFFINITY, Bimzelx, CIBINQO, COSENTYX, DUPIXENT, EBGLYSS, LIBTAYO, Leqselvi, NEMLUVIO, OPZELURA, OTEZLA, RINVOQ, Rhapsido, SIMPONI, SIMPONI ARIA, SKYRIZI, STELARA, Sotyktu, TALTZ, TREMFYA, Winlevi, Xolair, YCANTH, Zoryve | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error